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ABSTRACT
BPTF, a subunit of NURF, is well known to be involved in the development of 
eukaryotic cell, but little is known about its roles in cancers, especially in non-small-
cell lung cancer (NSCLC). Here we showed that BPTF was specifically overexpressed 
in NSCLC cell lines and lung adenocarcinoma tissues. Knockdown of BPTF by 
siRNA significantly inhibited cell proliferation, induced cell apoptosis and arrested cell 
cycle progress from G1 to S phase. We also found that BPTF knockdown downregulated 
the expression of the phosphorylated Erk1/2, PI3K and Akt proteins and induced the 
cleavage of caspase-8, caspase-7 and PARP proteins, thereby inhibiting the MAPK 
and PI3K/AKT signaling and activating apoptotic pathway. BPTF knockdown by 
siRNA also upregulated the cell cycle inhibitors such as p21 and p18 but inhibited the 
expression of cyclin D, phospho-Rb and phospho-cdc2 in lung cancer cells. Moreover, 
BPTF knockdown by its specific shRNA inhibited lung cancer growth in vivo in the 
xenografts of A549 cells accompanied by the suppression of VEGF, p-Erk and p-Akt 
expression. Immunohistochemical assay for tumor tissue microarrays of lung tumor 
tissues showed that BPTF overexpression predicted a poor prognosis in the patients 
with lung adenocarcinomas. Therefore, our data indicate that BPTF plays an essential 
role in cell growth and survival by targeting multiply signaling pathways in human 
lung cancers. 
INTRODUCTION
Lung cancer has become the first tumor in morbidity 
and mortality among males, and has been the leading 
cause of cancer death among females in more developed 
countries [1]. Although there is a rapid development in the 
treatment by targeted therapies, the five-year survival rate 
is still quite low, less than 16% all over the world [1, 2]. 
One of the main reasons for this is that poorly is known 
about the biology of lung cancer, so that we cannot find 
effective ways to cure it. Therefore, fully understanding 
the essence of the cell biology and molecular biology of 
lung cancer is a key way to conquer it.
It is well known that chromatin remodeling is 
closely associated with tumors [3, 4]. It is a basic 
procedure for eukaryotic gene expression [5]. DNA is 
tightly packaged in nucleus. Such condensed structure 
inhibits transcription factors binding to promoter 
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regions, which leads to restrain of gene expression. 
Numbers of evidence prove chromatin remodeling is 
essential for cell growth and division. Mutations in such 
chromatin remodelers and deregulated covalent histone 
modifications potentially make the cell growth out of 
control and then initiate cancers [6, 7]. For example, 
inactivating mutations in SMARCB1, a component 
of the human SWI/SNF remodeling complex, can 
lead to rhabdoid tumors [8]. Mutations in histone 
acetyl transferases (HAT) p300 are found in lung 
cancer, pancreatic, colorectal, breast cancer and so 
on [9–11].
Chromatin remodeling is carried out mainly 
by covalent histone-modifying complexes and ATP-
dependent chromatin remodeling complexes. The 
frontier includes histone acetyltransferases (HATs), 
deacetylases, methyltransferases and kinases; the later 
contains SWI/SNF, ISWI, NuRD/Mi-2/CHD, INO80 and 
SWR1 [12, 13]. NURF (nucleosome remodeling factor) 
is one of ISWI super family members. It was originally 
characterized in Drosophila, which worked in nucleosome 
assembly and spacing in vitro and regulated transcription 
of several hundreds of Drosophila genes in vivo, such as 
vital genes for fly development [14, 15]. NURF contains 
4 subunits in Drosophila, whereas it includes 3 subunits in 
human. Both of the NURFs are highly homologous, which 
strongly indicates that it has been conserved through 
evolution. Also it indicates that the factor has a basic and 
important effect on life [12, 16].
BPTF, called bromodomain PHD-finger 
transcription factor, is the largest unit of NURF. In the 
previous reports, most information about BPTF focused 
on the regulation of genes essential for the development 
of key tissues and chromatin remodeling [17–19]. BPTF 
was also reported to be able to regulate Erk expression 
in melenoma [26]. Although it is an indisputable fact that 
transcription factors are intimately associated with cancers, 
little is known about the roles of BPTF in cancers. Some 
authors reported that bptf gene was mutated in bladder 
cancer, and the mutated bptf gene could promote lung 
pre-malignant, which also showed knocking down bptf 
led to a dramatic reduction in colony formation [20, 21]. 
In addition, some authors reported that BPTF indicated 
a negative prognosis in patients with hepatocellular 
carcinoma [11]. All these researches indicate that BPTF 
may be a cancer-promoting protein. However, we know 
little about its biological behavior and its further molecular 
mechanisms in cancers, especially in NSCLC.
In this study, we examined the effects of BPTF on 
lung cancer cell proliferation, apoptosis and cell cycle, and 
further identified the underlying molecular mechanisms 
in vitro and in vivo. We also assessed whether BPTF 
expression was correlated with the overall survival in lung 
adenocarcinoma. Our findings therefore provide a new 
understanding about NSCLC tumorigenesis, and maybe 
support a fresh potential choice of therapeutic target for 
lung cancers.
RESULTS
BPTF was highly expressed in NSCLC cell lines 
and tumor tissues
We selected the human normal lung cell line HLF 
and 4 NSCLC cell lines (A549, NCI-H460, H322 and 
H1299) for our study. We checked the BPTF expression 
in NSCLC cell lines by Western Blot and RT-PCR 
(Figure 1A, 1B). Then we detected the percentage of 
positive BPTF expression in lung adenocarcinoma tissue 
by immunohistochemistry assay on a tissue microarray of 
75 cases with cancer tissues and adjacent nonmalignant lung 
tissues (Figure 1C). Immunohistochemical staining showed 
that lung tumor tissues had much higher expression of BPTF 
than their adjacent non-cancer tissues. Five representative 
cases (Case 1 to 5) were respectively from 5 different 
patients (Figure 1C). Among 75 patients’ tumor tissue 
samples tested, about 53 (70.7%) patients showed high 
expression of BPTF. These results indicated BPTF might 
be a potential biomarker for human lung cancer.
Knockdown of BPTF inhibited NSCLC cell 
growth and survival in vitro
To study the biological function of BPTF protein, 
we selected NSCLC cell lines (A549, H460, H322) as the 
cell models which highly expressed BPTF. Since the BPTF 
gene is quite large, it is hard to acquire the plasmid with the 
complete sequence of BPTF. Therefore, we applied RNA 
interference technology to study the function of BPTF in 
NSCLC cells. The non-specific small interfering RNA 
(siRNA) and BPTF-siRNAs were transfected into A549 
and NCI-H460 cells. 48 hours after treatment, BPTF was 
markedly down regulated in these 2 cell lines (Figure 2A). 
At the same time, knockdown of BPTF significantly 
inhibited cell viability by MTT assay (Figure 2B), and 
clone formation was also suppressed compared with the 
control group transfected with the non-specific siRNA 
(Figure 2C). These results showed that BPTF played a 
crucial role in cell proliferation of NSCLC cells.
Knockdown of BPTF inactivated MAPK and 
PI3K/AKT signaling pathways
To deliberate the molecular mechanism by which 
BPTF regulated cell proliferation in NSCLC cells, we 
detected a number of important proteins related with 
tumorigenesis by immunoblot (Figure 3). We found that 
when BPTF was knocked down, phospho-c-Raf, phospho-
MEK1/2, phospho-Erk1/2 and phospho-p90RSK were 
decreased in the MAPK pathway, while phospho-p38 
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Figure 1: BPTF was overexpressed in NSCLC cell lines and lung adenocarcinoma tissues. A. The expression of BPTF in 
human normal lung cell HLF and various NSCLC cell lines was analyzed by Western blot. B. The expression of BPTF in human normal 
lung cell HLF and various NSCLC cell lines was analyzed by RT-PCR. C. The expression of BPTF in human lung adenocarcinoma and their 
adjacent non-malignant lung tissues from 5 different patients with lung cancers (Case 1, 2, 3, 4 and 5) was detected by immunohistochemical 
staining (magnification, 200x and 400x).
and p38 were increased. In the PI3K/AKT pathway, 
phospho-p85, p110γ, phospho-PDK1, phospho-Akt 
and phospho-GSK-3β were also reduced. These results 
indicate that BPTF knockdown-mediated inhibition of cell 
proliferation may be associated with the inhibition of the 
MAPK and PI3K/Akt pathways in NSCLC cell lines.
BPTF knockdown induced cell apoptosis
To investigate the effect of BPTF on cell 
apoptosis, we performed Annexin V-PI staining-based 
FACS analysis. Knockdown of BPTF led to the increase 
of approximately 15%–20% of apoptotic cells compared 
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with the control group in A549 and NCI-H460 cell lines 
(Figure 4A and 4B). To confirm this, we also analyzed 
the apoptosis-related molecules by Western blot. As 
shown in Figure 4C and 4D, knockdown of BPTF 
effectively increased the levels of cleaved caspase-8, 
cleaved caspase-7 and cleaved PARP1, but decreased the 
levels of Apaf-1, cleaved caspase-9 in NCI-H460 cells. 
These results indicate that BPTF plays an important role 
in the regulation of apoptosis in lung cancer cells.
BPTF knockdown inhibited cell cycle progress 
from G1 to S phase
We next assessed the effect of BPTF on cell cycle 
progress by a PI staining-based FACS analysis in A549 
and H322 cell lines transfected with BPTF siRNA. 
As shown in Figure 5B and 5C, knockdown of BPTF 
resulted in more staining of cells in the G1 phrase but 
less cell staining in the S phrase by comparison with the 
Figure 2: Knockdown of BPTF inhibited proliferation of NSCLC cells. A. The expression of BPTF in A549 and NCI-H460 
cell lines were analyzed by Western blot after transfected with BPTF siRNA. Mock, non treatment; control siRNA, non specific siRNA; 
BPTF siRNA-1 and BPTF siRNA-2, BPTF specific siRNA. B. Cell viability of A549 and NCI-H460 cells was measured by MTT assay. 
The mean and SD value got from 3 independent experiments are marked (*P < 0.05; **P < 0.01). C. Colonies (>50 μm) were counted 
10–12 days in A549 and NCI-H460 cells after transfected by siRNA . Each bar represents the mean colony number and SD of 3 wells (*P < 
0.05; **P < 0.01).
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nonspecific-siRNA group. Also, we detected the relevant 
vital proteins involved in cell cycle regulation from 
G1 to S phrase and cell cycle check points by Western 
blot (Figure 5D). We found that knockdown of BPTF 
inhibited the expression of cyclin D1 and phospho-
Rb; whereas p21 and p18 were enhanced by BPTF 
knockdown compared with the control groups.
BPTF predicted a poor prognosis in lung 
adenocarcinomas
To further reveal the clinicopathologic 
significance of BPTF in lung adenocarcinomas, tissue 
microarray immunohistochemistry assay for 75 cases 
of lung adenocarcinomas was analyzed. The results 
Figure 3: Knockdown of BPTF suppressed MAPK and PI3K-AKT signaling pathways. A. The key protein in MAPK 
pathways were detected by immunoblot in A549 and NCI-H460 cells 3 days after transfected by siRNA. B. The proteins in PI3K-AKT 
pathway in A549 and NCI-H460 were analyzed by Western blot 3 days after siRNA transfection.
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showed that high expression of BPTF was associated 
with N (lymph node metastasis) and clinical staging 
factors (P < 0.05) according to Pearson chi-square 
test (Table 1A). N, clinical stage and BPTF expression 
were also associated with survival of the patients with 
lung adenocarcinomas based on Univariate analysis 
of Cox regression model (Table 1B). Furthermore, 
multivariate analysis revealed that the clinical stages 
and BPTF expression were the influencing factors to 
lifetime of lung adenocarcinomas (Table 1B). We also 
used Kaplan–Meier analysis to analyze the difference 
of overall survival between high and low BPTF 
expression (Figure 6B). The results showed that high 
expression of BPTF was negatively associated with the 
overall survival, indicating that BPTF predicted a poor 
prognosis in lung adenocarcinomas.
Knockdown of BPTF by shRNA inhibited 
NSCLC cell growth in vitro and in vivo
The effect of BPTF on lung cancer growth was 
further proved by using BPTF shRNA in vitro and in vivo. 
First of all, cell viability was measured by MTT assay at 
48 h after A549 and NCI-H460 cell lines were transfected 
with control shRNA and BPTF specific shRNA. The results 
showed BPTF expression were markedly knocked down 
by its specific shRNA (Figure 7A) and its silencing led to 
the inhibition of cell viability in A549 and H460 cell lines 
(Figure 7B). To determine the role of BPTF in the regulation 
of tumor growth in a lung cancer mouse model in vivo, 
A549 cells were injected subcutaneously into the armpit 
of nude mice. When the tumor grew to 5 × 5 cm (lenth × 
width) in size, the animals were classified into 2 groups with 
5 nude mice each group. The BPTF shRNA and control 
shRNA were respectively injected into nude mice every 4 
days. The tumor volume was measured and recorded every 
4 days too. 24 days later, animals were sacrificed and tumors 
were isolated to be weighted and examined. Compared to 
the control shRNA treated group, the tumor volume and 
weight were significantly reduced in the group treated with 
the BPTF shRNA (Figure 7C, 7D). Next, we also examined 
the effect of BPTF shRNA on the expression of some key 
proteins in the tumor tissues by Western blot. Compared 
to the control shRNA-treated group, the expression of 
VEGF, p-Erk, and p-Akt was markedly attenuated in the 
group treated by BPTF shRNA, while the expression of 
P21 and BCL-2 was improved (Figure 7E). All these results 
demonstrated again the silencing of BPTF inhibited lung 
tumor growth in vitro and in vivo.
DISCUSSION
As the largest unit of NURF, BPTF is involved 
in chromatin remodeling which is a key process for 
eukaryotic cell. It is reported that BPTF facilitates gene 
transcription and accelerates cell development [12, 17, 18]. 
As a chromosome-mediated transcription factor, BPTF 
simultaneously recognizes 2 different histone modifications. 
The PHD finger of BPTF can bind dimethylated 
and trimethylated H3K4 (H3K4me2/3). Its adjacent 
bromodomain interacts with H4 peptides acetylated at K12, 
K16, or K20 [22–24]. Its function as a transcription factor 
is closely related with tumorigenesis. Francisco X Real 
identified BPTF gene recurrently mutated in bladder cancer 
by the method of exome sequencing [20]. Varda Rotter 
detected 17q24.3 region in the BPTF locus and found BPTF 
was associated with lung premalignant and 27% of lung 
tumors exhibited gain of 17q24.3 [21]. Also, Lu’s group 
reported that there was some relationship between BPTF 
and hepatocellular carcinoma [25]. Most importantly, 
Altaf A. Dar demonstrated the vital role in melanoma 
progression [26]. Similarly, we detected the expression of 
BPTF protein expression in 75 lung adenocarcinomas and 
found 71% of them were positive. These results indicate 
BPTF is a novel biomarker in lung cancers.
In this study, we also investigated the biological 
functions of BPTF on cell growth, apoptosis and 
cell cycle, and found that BPTF played a key role in 
promoting cell proliferation, inhibiting cell apoptosis 
and accelerating cell cycle. The result of colony 
formation was similar to the previous reports that 
BPTF knockdown led to a great reduction in colony 
formation in lung, bladder cancer and melenoma 
[20, 26]. Especially, we proved BPTF has marked effect 
on tumor growth in vivo. In addition, we also identified 
the underlying mechanisms of these biological functions 
in vitro and in vivo. We found BPTF significantly 
promoted cell proliferation mainly by regulating the 
MAPK and PI3K-AKT pathways, which was similar to 
the report in melanoma but different from the report that 
BPTF promoted cell development and differentiation 
through TGF-Smad pathway [17, 26]. It is well known 
that extracellular regulating kinase (ERK) pathway is 
markedly related with cell proliferation, transforming 
and differentiation [27]. It is worth recalling here 
that the upstream protein c-Raf in ERK pathway was 
influenced, and the proteins in this pathway were also 
reduced subsequently after BPTF was knocked down. In 
contrast, another key protein involved in carcinogenesis 
and development, p38, was up-regulated by BPTF 
knockdown. The phospho-p85, an upstream protein in 
PI3K-AKT pathway, was down-regulated when BPTF 
was knocked down, which resulted in a reduction of the 
downstream proteins in this pathway, such as phospho-
PDK1, phospho-Akt, and phospho-GSK-3β.
It is known that Raf is activated by RAS, which 
is stimulated by the active receptor tyrosine kinases 
(RTKs) in MAPK pathway[27]. Also, in PI3K-AKT 
pathway, autophosphorylation of ligand-activated receptor 
tyrosine kinases (RTKs) causes recruitment of inactive 
heterodimeric class IA phosphatidylinositol 3-kinases 
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(PI3Ks) through the interaction of phosphotyrosine 
residues on the receptor and SRC-homology 2 (SH2) 
domains on the PI3K p85 regulatory subunit. These 
SH2–phosphotyrosine interactions bring PI3K in close 
proximity to its substrate at the plasma membrane and 
relieve the inhibitory action of p85 on the p110 catalytic 
subunit, which is then free to convert PtdIns(4,5)P2 (PIP2) 
into PtdIns(3,4,5)P3 (PIP3). Alternatively, binding of 
PI3K to activated RAS can also stabilize its membrane 
localization and activate the catalytic domain [28, 29]. 
Therefore, both of the pathways are activated by RTKs 
and RAS. In this study, knockdown of BPTF decreased 
the expression level of c-RAF and p-P85, the respective 
upstream proteins in the PI3K-AKT and MAPK pathways. 
Therefore, we speculate BPTF might promote the NSCLC 
proliferation by affecting the activity of RAS or RTKs. 
Figure 4: Knockdown of BPTF activated apoptosis by caspase-dependent pathway. A. A549 and NCI-H460 cells transfected 
with siRNA for 3 days were analyzed by FACS using an Annexin V-FITC/PI-staining kit. B. Apoptosis was calculated in terms of the 
FITC-positive in cells. Each bar represents the mean and SD value of 3 experiments (**P < 0.01; ***P < 0.001). C. NCI-H460 cells with 
knockdown of BPTF were analyzed by Western blot with antibodies of Apaf-1, cleaved caspase-9, BCL-2, cleaved caspase-8, caspase-7 
and PARP1. D. The quantitative analysis for the cleaved caspase-8.
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Figure 5: Knockdown of BPTF inhibited cell cycle. A. BPTF was analyzed by Western blot in A549 and H322 cell lines transfected 
with BPTF siRNA for 3 days. B. Cell cycle of A549 and H322 cells with knockdown of BPTF was tested by FACS. C. Cell cycle was 
analyzed in terms of peaks of G1, S and G2/M. Each bar represents the SD from 3 independent experiments. D. Key proteins associated 
with cell cycle were detected by Western blot.
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Furthermore, we checked VEGF expression when BPTF 
was knockdown by transecting BPTF shRNA in vivo. The 
result showed the VEGF were obviously down-regulated 
after BPTF was knocked down. Therefore, we speculated 
BPTF as a transcriptional factor regulated the expression 
of VEGF. When VEGF binds to VEGFR, the latter occurs 
autophosphorylation and then activates the downstream 
molecular such as Ras and P85 in the pathways of MAPK 
and PI3K.
We also discovered that BPTF restrained 
NSCLC apoptosis by regulating the activation of 
caspase-8, caspase-7 and PARP1 proteins. Apoptosis 
pathway includes mitochondrial regulation, direct 
signal transduction, and endoplasmic pathways [30]. 
We analyzed the mitochondrial regulation pathway 
by detecting related proteins, but unfortunately, we 
found that knockdown of BPTF up-regulated BCL-2 
and down-regulated Apaf-1 and cleaved caspase-9 in 
Table 1A: Association of BPTF with clinicopathological features in 75 cases with lung 
adenocarcinoma
Total (n = 75) BPTF high expression (n = 51) BPTF low expression (n = 24) P
Gender
 Male 39 23 (59%) 16 (41%) 0.081
 Female 36 28 (77.8%) 8 (22.2%)
Age
 <60 38 25 (65.8%) 13 (34.2%) 0.737
 > = 60 36 25 (69.4%) 11 (30.6%)
T
 T1 + T2 63 41 (65.1%) 22 (34.9%) 0.336
 T3 + T4 12 10 (83.3%) 2 (16.7%)
N
 N0 + N1 52 29 (55.8%) 23 (44.2%) 0.011
 N2 + N3 12 12 (100%) 0 (0%)
Clinical Stage
 Stage I 34 18 (52.9%) 16 (47.1%) 0.013
 Stage II 12 6 (50.0%) 6 (50.0%)
 Stage III 16 15 (93.8%) 1 (6.3%)
 Stage IV 3 3 (100%) 0
Table 1B: Cox regression model analysis of prognostic factors in 75 cases with lung adenocarcinoma
RR 95%CI Unfaourable/Favourable P
Univariate analysis
 T 2.255 1.606–4.797 T1+T2/T3+T4 0.035
 N 5.354 2.475–11.582 N0+N1/N2+N3 0.000
 Clinical Stage 1.804 1.321–2.464 Stage I/II/III/IV 0.000
 BPTF 8.543 2.587–28.217 High/Low 0.000
Multivariate analysis
 Clinical Stage 1.971 1.355–2.868 Stage I/II/III/IV 0.000
 BPTF 8.034 2.244–28.762 High/Low 0.001
Abbrevations: RR, relative risk; CI, confidence interval
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the NCI-H460 cell line. The results indicated NSCLC 
apoptosis induced by BPTF may not be realized through 
the mitochondrial pathway. Considering that knockdown 
of BPTF increased the expression of cleaved caspase-8, 
it is possible that BPTF restrained apoptosis via the 
death receptor pathway, which needs to be further 
proved.
Furthermore, we detected BPTF-mediated effect 
on cell cycle in lung cancer A549 and H322 cells. 
Although the efficiency of BPTF knockdown by siRNAs 
was different, the cell cycle was obviously blocked 
from G1 to S phrase. We also detected the cell cycle 
related proteins by Western blot to investigate the 
deeper molecular mechanisms. As a chief external signal 
sensor, CyclinD plays a major role in the middle of G1 
phase. Growth signals passed by Ras-Raf-MEK-MAPKs 
signal transduction pathway could finally enter nuclei 
and activate CyclinD1. By combining with CDK4/6, 
CyclinD1 is further activated to accelerate cell cycle 
by phosphorylating Rb and inactivating the latter. 
By contrast, when the level of phosophorylated Rb is 
attenuated, through binding to the transcriptional factor 
E2F, it could inhibit the transcriptional activity of E2F, 
thus suppressing cell cycle from G1 to S phase. Instead, 
if Rb is phosphorylated, E2F promotes transcription 
of many genes, thus starting a cell to enter S phase 
[31–34]. The stability of Cyclin D itself is controlled 
by glycogen synthesis protein kinase -3beta, GSK-3β. 
Under the condition of lacking of growth signals, GSK-
3β is able to be activated to phosphorylate Cyclin D and 
promote its degration. As a result, cell cycle is blocked. 
In this study, we found that the knockdown of BPTF 
Figure 6: BPTF predicted a poor prognosis in lung adenocarcinoma. A. Typical examples for negative, weak, moderate and 
strong BPTF expression in lung adenocarcinoma tissues (Magnification 200X). B. Overall survival of lung adenocarcinoma patients with 
high or low BPTF expression was analyzed by Kaplan-Meier analysis.
Oncotarget33888www.impactjournals.com/oncotarget
could down-regulate the levels of phosphor-AKT and 
phospho-GSK-3β, and then reduced the expression of 
Cyclin D1 and phospho-Rb, and further inhibited cell 
cycle. As CDK kinase inhibitor, p18 and p21 were 
up-regulated [35–37]. We can also see P21 was up-
regulated when BPTF was knocked down by shRNA 
in vivo. All the data well explained the molecular 
mechanism of the blocking from G1 to S phase in 
cell cycle caused by knockdown of BPTF. Moreover, 
we tested phospho-cdc2 involved in the checkpoints 
from G2 to M and found that it was decreased in BPTF 
knockdown groups, indicating that BPTF might inhibit 
Figure 7: Knockdown of BPTF by shRNA inhibited lung cancer cell growth in vitro and in vivo. A. The expression of BPTF 
in A549 and NCI-H460 cell lines were analyzed by Western blot after transfected with non-specific control shRNA or BPTF shRNA. B. 
Cell viability of A549 and NCI-H460 cells was measured by MTT assay. The mean and SD value got from 3 independent experiments are 
marked (*P < 0.05; **P < 0.01). C. Tumor growth curves in xenografts of A549 cells for each group (n = 5). Dots represent the mean, while 
bars indicate the SD. (*P < 0.05). D. Tumor graft from the 2 different groups treated with BPTF shRNA and Control shRNA respectively. 
E. The expression of BPTF, VEGF, P-Erk, P-Akt, P21, BCL-2 and GAPDH were examined from 3 pairs of tumor xenografts in non-specific 
control shRNA and BPTF-specific shRNA-treated nude mice by Western blot. “C” means control shRNA, and “B”means “BPTF shRNA”.
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cell cycle from G2 to M phrase too [38]. Taken together, 
we showed that BPTF was a key factor to promote cell 
cycle in NSCLC.
We also found BPTF was highly expressed in 
NSCLC cell lines and tumor tissues compared to the 
normal cell or adjacent tissues. However, in our study, 
we found the high expression of BPTF at mRNA level 
but low expression at protein level in H1299 cells. 
This probably resulted from the post-translational 
modification of BPTF. The exact regulatory mechanism 
for this possible post-translational modification deserves 
a further study.
To see whether BPTF played a vital role in human 
clinical samples, we analyzed the data from 75 cases with 
lung adenocarcinoma. We found the high expression of 
BPTF was associated with N (lymph node metastasis) 
and clinical staging factors. It was reported that VEGF 
was closely related with lymph node metastasis and 
tumor angiogenesis. We found VEGF was decreased 
with the knockdown of BPTF in vivo. Therefore, it is 
possible that the association of BPTF with N ( lymph 
node metastasis) is through its effect on VEGF. Lifetime 
of lung adenocarcinoma was associated with clinical 
stage and BPTF expression. We also have demonstrated 
that the overall survival of patients with high BPTF is 
shorter than that with low BPTF expression according to 
Kaplan–Meier analysis. Therefore, BPTF is not only a 
key factor in vitro or in nude mice, but also a crucial one 
in human tissues.
Collectively, our results demonstrate that BPTF 
plays an essential role in NSCLC cell survival, and it may 
be a potential therapeutic target for NSCLC.
MATERIALS AND METHODS
Cell lines and cell culture
Human normal lung fibroblast (HLF-1), human 
NSCLC cell lines (A549, NCI-H460, H322, and H1299) 
were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). HLF-1 was cultured 
in F12K medium. A549 was cultured in DMEM/F12 
medium. H322, NCI-H460 and H1299 were cultured in 
RPMI-1640 medium. All the mediums were supplemented 
with 10% fetal bovine serum (Biological Industries, Israel) 
and produced by Invitrogen Company (Carlsbad, CA). 
Cells were maintained in a humidified atmosphere and 
5% CO
2
 at 37°C.
Western blot analysis
Protein samples with proteinase and phosphatase 
inhibitors (Thermofisher, USA.) were mixed with SDS 
sample loading buffer and resolved by PAGE. 30–40 μg 
total protein was transferred to 0.22 μm or 0.45 μm 
PVDF (Millipore, Germany) overnight at 20–30 V limits. 
Membranes were blotted with antibodies of BPTF 
(Abcam, USA) at 1:2000, β-actin ( proteintech, USA) at 
1:5000, GAPDH (Proteintech, USA) at 1:5000, phospho-
PI3Kp85(Tyr458)antibody (CST, USA) at 1:1000, PI3K 
p110-γ (CST, USA) at 1:1000, Phospho-p38 (Thr180/
Tyr182) (3D7) (CST, USA) at 1:1000, p38 at 1:1000, 
Cleaved Caspase-7 (Asp198) at 1:1000, BCL-2 (Proteintech, 
USA) at 1:1000, Cleaved PARP (Asp214) (D64E10) (CST, 
USA) at 1:1000, Phospho-cdc2 (Tyr15) (10A11) (CST, 
USA) at 1:1000, Phospho-Rb (Ser795) (CST, USA) at 
1:1000, Phospho-p53(Ser15) (16G8) (CST, USA) at 1:1000, 
and Phospho-Akt (Thr308) (CST, USA) at 1:1000, Phospho-
Erk1/2 Pathway Antibody Sampler Kits (CST, USA) at 
1:1000, adding cell cycle regulation antibody sampler kit 
(CST, USA) at 1:1000 and Cell Cycle/Checkpoint Antibody 
Sampler Kit at 1:1000 overnight at 4°C, then anti-rabbit 
or mouse HRP (Proteintech, USA) at 1:5000–1:10000 
dilutions for about 2 hrs at RT in TBST. At last, protein 
brands were detected by ECL (Advansta, USA) according 
to manufacturer’s procedures.
RT-PCR
Total RNA was extracted and reversely transcribed 
into cDNA according to the instructions of RNAiso 
Plus kit and PrimeScript TM RT reagent Kit with gDNA 
Eraser (TaKaRa, China). The cDNA was amplified by 
PCR following the protocol of TaKaRa Taq TM Hot Start 
Version (TaKaRa, China). The sequence of forward primer 
of BPTF was 5′-AATCGGAGAAGTCCAACGGG-3′; 
the sequence of reward primer of BPTF was 
5′-TTGCCCTATGTGATGCCCAG-3′. They were 
produced by life Technologies Company (Invitrogen, 
Carlsbad, USA).
Human lung adenocarcinoma tissue microarray
The human lung adenocarcinoma tissue microarray 
was purchased from Shanghai Outdo Biotech (China) 
consisting 75 cases with lung adenocarcinoma and their 
adjacent non-malignant lung tissues. These cases had got 
nothing anticancer therapies before tumor resection. We 
have the detailed clinical and pathological information, 
including age, sex, chief complaints, TNM stage, and 
overall survival (OS) duration and so on.
Transient transfection of siRNA
siRNAs were synthesized by Shanghai Genepharma 
Company (China). Non specific siRNA and three 
BPTF-siRNAs were designed. Two of the three BPTF 
si-RNAs were effective, and for the knockdown 
efficiency, BPTF siRNA-1 was not as validated as 
BPTF si-RNA-2. Their sequences were: non specific 
siRNA: 5′-UUCUCCGAA CGU GUCACGUTT-3′ 
and 5′-ACGUGACACGUUCGGAGAATT-3′; 
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BPTF-siRNA-1 (BPTF-homo-1550): 
5′-GGUCCAACUUGCAGAAUUATT-3′ 
and 5′-UAAUUC UGCAAGUUGGAC CTT-
3′; BPTF-siRNA-2 (BPTF-homo-6959): 
5′-GACCCA AACAACUGUUUCATT-3′ and 
5′-UGAAACAGUUGUUUGGGUCTT-3′. The procedure 
of transfection was as followed. First, cells were seeded 
into each well of a six-well tissue culture plate and 
estimated at 60–80% cell confluency the next day. At the 
same time, put the well mixed reagent with RNAiMax 
(Invitrogen, Carlsbad, USA) and siRNA into still 
suspending cells following the instruction of RNAiMax. 
The next day, when cells adhered onto culture plates, we 
change the culture medium with 10% FBS but without 
antibiotics. After 48 or 72 hrs, cells were collected and the 
related experiments were done.
Transient transfection of shRNA
ShRNAs were purchased from Gene Copoeia 
Company(U.S.A). Four shRNAs were designed, and one 
of them was the most effective (Catalog No.: HSH005096-
LVRH1MP and CSHCTR001–1-LVRH1MP). According 
to the lipofectamine 3000 protocol (Invitrogen, U.S.A), 
control shRNA and BPTF specific shRNA were transfected 
into A549 and NCI-H460 cell lines. After 48 h, MTT assay 
was used to measure cell viability.
Cell proliferation and colony formation assay
Cell proliferation was estimated by ways of MTT 
(Promega) array according to the manufacturer’s protocol. 
Cell viability was measured after 24, 48 and 72 hrs. At 
last, it was identified that the difference was the most 
obvious when cells were transfected for 72 hrs. To do 
colony formation assay, 1000 cells were seeded into each 
well of six-well plates, at the same time the cells were 
transfected with siRNAs. The next day, changed new 
culture medium with antibiotic, cells was put into the 
incubator again. Cells were cultured for about 12 days 
without any disturbing, and colonies were stained with 
crystal violet for 10–30 minutes at RT. At last colonies 
were counted by eyes.
Apoptosis and cell cycle assay
Cells (A549 and NCI-H460) transfected with 
si-RNA were analyzed by flow cytometry to detect 
apoptosis. After 72 h, the transfected cells were 
stained with Annexin V-FITC and PI (propidium 
iodide) according to the instruction of Keygen 
Annexin V-EGFP Apoptosis Detection Kit (China) 
and were placed on ice for 5–15 minutes in the dark. 
Then samples were examined by flow cytometry 
(BD FACScalibur).
Cell cycle analysis was carried out by PI staining 
(Sigma, USA). The transfected cells for 72 h were 
harvested and fixed in 70% cold ethanol overnight (not 
more than 1 week). After removing  the disturbed RNA 
by adding RNase (Thermofisher, USA) at 37°C for 30 
minutes, cells were stained with PI on ice for 10–20 
minutes. At last, samples were performed by flow 
cytometry (BD FACScalibur).
Immunohistochemistry
The tissue microarray slides were deparaffinized in 
xylene and rehydrated through graded alcohol. Antigen 
retrieval was performed by incubating samples with 
Target Retrieval Solution (pH 9; DakoCytomation) for 
15 minutes using a pressure cooker. Then the slides 
were immersed in methanol containing 3% hydrogen 
peroxide for 20 minutes to block endogenous peroxidase 
activity. After preincubation in 2.5% blocking serum 
to reduce nonspecific binding, the sections were 
incubated overnight using primary antibody, anti-BPTF 
(Bethyl, 1:50 dilution), in a humiditified container at 
4°C. The tissue microarray slides were processed with 
horseradish peroxidase immunochemistry according to 
the manufacturer’s recommendations (DakoCytomation, 
CA). As a negative control, the staining procedure was 
performed with the primary antibody replaced by a 
normal rabbit IgG. Staining intensity was graded as: 
absent staining as “-”, weak as “+”, moderate as “++”, 
strong as “+++”. Because each tissue on the tissue 
microarray slides was quite small, we could not determine 
the grade of percentage of stained cells. Staining tissues 
with “++”, “+++” were determined as “high expression of 
BPTF”, but the other tissues with “-” and “+” were judged 
as “low expression of BPTF”. The result was identified by 
two senior pathologists.
Statistical analysis
Pearson chi-square test was used to analyze 
the relationship among BPTF and gender, age, T, N, 
clinical stage. Cox regression model was performed to 
analyze factors related to survive. We adopted stepwise 
regression model: Forward: LR, selected variables 
(P ≤ 0.05); Eliminating variables (P > 0.05). Univariate 
analysis was used to assess the relation of gender, age, 
T, N, clinical stage and BPTF expression to oversurvival 
of lung adenocarcinoma. And multivariate analysis was 
performed to further show the influent factors to overall 
survival of lung adenocarcinoma. At last, Kaplan–
Meier analysis was performed to assess the association 
between the overall survival and BPTF expression. 
P value < 0.05 was considered statistically significant 
in all cases.
Animal experiments
Animal experiments were carried out according to 
the National Institue of Health Guide for the Care and 
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Use of Laboratory Animal under the approval of APF 
laboratory Animal Center at Dalian Medical University. 
A549 cells (5 × 106) were planted subcutaneously under 
the left arms of nude mice. After about 14 days, tumors 
grow to 5 mm × 5 mm (length × width), and the nude mice 
were classified into 2 groups. There was no difference 
between the 2 groups on tumor volumes and the size of 
nude mice. Group 1 was set as control shRNA , and Group 
2 was BPTF shRNA . According to lipofectemine 3000 
protocol, we transfected shRNA plasmids into tumors. 
25 μg shRNA in 100 μl liposome was injected per 4 days 
for 20 days. The tumor volume was calculated in terms of 
“Volume = (width2 × length)/2” using digital calipers. In 
the end, the nude mice were sacrificed for further checking 
the expression of related proteins by Western blot.
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